February 12, 2025
When there is blood on the street, it’s time to BUY or was it the reverse of words
Suppositions - a formal word for an idea that you think is true although you may not be able to prove
Earnings: Losses, revenue lags, clinical progress with some program uncertainty, a dearth all followed by estimate misses with an although see … Companies in my headlights
I am NOT often wrong and always consider doubt of some market and sector share pricing movements
Never leave an investor uninform
January 27, 2025
Breaking: SAGE board has unanimously rejected Biogen’s (BIIB) $469 M offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests. BIIB, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. SAGE also announced it has initiated a process to explore strategic alternatives but has not set a timeline for the review.
SAGE confirmed (2/10/25) that Biogen (BIIB) has submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of SAGE not already owned by BIIB for $7.22 per share.
SAGE is trading (Monday, 1/27/25) up +$0.39 or -5.42% at $7.49
February 14, 2025
As ½ of February erodes with inflation updates, tariff/trade levy reveals, retail data and as earnings reports roll-in
It’s hard to be right so often, it’s about defining insight. Who speaks out while standing in-front, beside and behind investors – RMi
I say today what others won't, so you can do what others can't!
Never leave an investor uninformed!
The Week in Review
January 27, 2025
Breaking: SAGE board has unanimously rejected Biogen’s (BIIB) $469 M offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests. BIIB, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. SAGE also announced it has initiated a process to explore strategic alternatives but has not set a timeline for the review. SAGE confirmed (2/10/25) that Biogen (BIIB) has submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of SAGE not already owned by BIIB for $7.22 per share. SAGE is trading (Monday, 1/27/25) up +$0.39 or -5.42% at $7.49
January 1, 2025
“Last year's words .... belong to last year's language. And next year's words ... await another voice” — TS Eliot
December 23, 2024
To RegMed Investor (RMi) readers, one and all … It’s been quite the year, 2024; more bottoms than peaks, a blend of fortune and losses. To you ... Christmas and Holiday wishes go a long way in maintaining relationships that have created bonds that WILL only become stronger with time. Whether you've been reading my insights from writings; I have been pretty damn right through the year! 2025 is just another road to be traveled … in safety! So, as you navigate the holiday hustle, remember to take a moment for some well-deserved relaxation and maybe a cocktail or two. Wishing you all a holiday season and fewer reasons to check your email!